List of Livalo drug patents
Livalo is owned by Kowa Co.
Livalo contains Pitavastatin Calcium.
Livalo has a total of 4 drug patents out of which 0 drug patents have expired.
Livalo was authorised for market use on 03 August, 2009.
Livalo is available in tablet;oral dosage forms.
Livalo can be used as adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia.
The generics of Livalo are possible to be released after 19 August, 2024.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8557993 | KOWA CO | Crystalline forms of pitavastatin calcium |
Feb, 2024
(10 months from now) | |
| US7022713 | KOWA CO | Hyperlipemia therapeutic agent |
Feb, 2024
(10 months from now) | |
|
US8557993
(Pediatric) | KOWA CO | Crystalline forms of pitavastatin calcium |
Aug, 2024
(1 year, 4 months from now) | |
|
US7022713
(Pediatric) | KOWA CO | Hyperlipemia therapeutic agent |
Aug, 2024
(1 year, 4 months from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Patient Population (NPP) | May 16, 2022 |
| Pediatric Exclusivity (PED) | Nov 16, 2022 |
Drugs and Companies using PITAVASTATIN CALCIUM ingredient
Market Authorisation Date: 03 August, 2009
Treatment: Adjuncitve therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein b, triglycerides and to increase hdl-c in adult patients with primary hyperlipidemia or mixed dyslipidemia
Dosage: TABLET;ORAL
LIVALO family patents
16
United States
15
Japan
6
European Union
4
Taiwan, Province of China
4
China
2
Germany
2
Poland
2
Canada
1
Portugal
1
Slovenia
1
Korea, Republic of
1
Hong Kong
1
Australia
1
Denmark
1
Austria
1
Spain
1
Cyprus
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic